ASTX030

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Near Add Your Location

Sorting 15 by

Center of Excellence

John Theurer Cancer Center at Hackensack University Medical Center 
Hackensack Meridian Health
Hackensack, NJ
  • Accepting patients

Center of Excellence

Roswell Park Cancer Institute
Buffalo, NY
  • Accepting patients

Center of Excellence

Vanderbilt-Ingram Cancer Center
Henry-Joyce Cancer Clinic
Nashville, TN
  • Accepting patients

Center of Excellence

MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients

Center of Excellence

Fred Hutchinson Cancer Research Center
University of Washington Cancer Consortium / SCCA
Seattle, WA
  • Accepting patients
Oregon Health and Science University
OHSU Knight Cancer Institute
Portland, OR
  • Accepting patients

Center of Excellence

USC Norris Comprehensive Cancer Center - Keck School of Medicine
University of Southern California
Los Angeles, CA
  • Accepting patients

Center of Excellence

Smilow Cancer Hospital at Yale New Haven
New Haven, CT
  • Accepting patients

Center of Excellence

Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.